Drs. Andrew Zelenetz and Jeffrey Crawford discuss two different cases and review the data and considerations for switching from a reference biologic to a biosimilar.
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
Copyright © 2016 by American Society of Hematology